EUCTR2015-005683-41-DKActive, not recruitingPhase 1
REDUCING THE IMPACT OF OVARIAN STIMULATION - THE RIOT PROJECT RIOT STUDY B: MAPPING THE ENDOCRINE DETERMINANTS OF OVARIAN STIMULATION TO OPTIMIZE OUTCOMES IN FRESH EMBRYO TRANSFER CYCLES
Sven O. Skouby, Professor, MD, DMSc. Unit of reproductive Medicine, Herlev/Gentofte Hospital0 sites32 target enrollmentStarted: January 7, 2016Last updated:
Conditions
Drugs
Trial Snapshot
- Phase
- Phase 1
- Status
- Active, not recruiting
- Sponsor
- Enrollment
- 32
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional clinical trial of medicinal product
Eligibility Criteria
- Sex
- Female
Inclusion Criteria
- •INCLUSION CRITERIA
- •Indication for IVF/ICSI treatment
- •Eligible for IVF/ICSI treatment according to local criteria
- •IVF/ICSI treatment with single embryo transfer
- •Regular cycles 21-35 days (both included)
- •Age < 40 years
- •AMH 8-32 (both included)
- •Written consent
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 32
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
Exclusion Criteria
- •EXCLUSION CRITERIA
- •Any contraindication for IVF/ICSI treatment according to local criteria
- •Previous stimulation for IVF/ICSI with < 4 oocytes obtained
- •Undergoing IVF/ICSI for the purpose of fertility preservation
- •Allergy towards study drug
Investigators
Similar Trials
Active, not recruiting
Phase 1
RIOT STUDY A: IS THERE A BETTER CHANCE OF ACHIEVING PREGNANCY UNDER FERTILIZATION TREATMENT WHEN AN AROMATASE INHIBITOR IS ADDED TO THE TREATMENT?InfertilityEUCTR2015-005682-24-DKSven Olaf Skouby, Professor, MD, DMSc. Unit of Reproductive Medicine, Herlev/Gentofte Hospital128
Active, not recruiting
Phase 1
RIOT C: REDUCING THE IMPACT OF OVARIAN STIMULATION BY ADDING CO-TREATMENT AROMATASE INHIBITOR.Ovarian stimulation in oocyte donationMedDRA version: 20.0Level: LLTClassification code 10071130Term: Controlled ovarian stimulationSystem Organ Class: 100000004865MedDRA version: 20.0Level: LLTClassification code 10072100Term: Egg donorSystem Organ Class: 100000004869EUCTR2017-004433-93-DKicholas Stephen Macklon, Professor, MD, PhD26
Completed
Phase 2
Mapping the Endocrine Determinants of Ovarian Stimulation to Optimize Outcomes in Fresh Embryo Transfer CyclesInfertilityNCT02939898Sven O. Skouby33
Completed
Phase 2
Effect of Addition of Aromatase Inhibitor to Ovarian Stimulation Therapy in IVF TreatmentInfertilityNCT02946684Sven O. Skouby129
Active, not recruiting
Phase 1
INTEnsity of ovariaN Stimulation and Embryo QualityTo compare the number of GQB and the morphokinetic parameters of early embryo development in infertile suboptimal patients undergoing two different intensities of ovarian stimulation, a milder approach ( Clomiphene Citrate (CC) 50mg/day plus 150IU daily dose of rFSH) and a more intense approach (300IU daily dose of rFSH).MedDRA version: 20.0Level: PTClassification code 10021928Term: Infertility femaleSystem Organ Class: 10038604 - Reproductive system and breast disordersMedDRA version: 21.0Level: PTClassification code 10021926Term: InfertilitySystem Organ Class: 10038604 - Reproductive system and breast disordersMedDRA version: 20.0Level: LLTClassification code 10021930Term: Infertility NOSSystem Organ Class: 10038604 - Reproductive system and breast disordersMedDRA version: 20.0Level: PTClassification code 10021929Term: Infertility maleSystem Organ Class: 10038604 - Reproductive system and breast disordersMedDRA version: 20.1Level: LLTClassification code 10016399Term: Female infertility (primary)System Organ Class: 10038604 - Reproductive system and breast disordersMedDRA version: 21.1Level: LLTClassification code 10039843Term: Secondary infertility (female)System Organ Class: 10038604 - Reproductive system and breast disordersEUCTR2021-000941-42-ESFundacion Santiago Dexeus Font100